4D Molecular Therapeutics stock surges over 25% on strong earnings report

Trending News ☀️

FDMT Stock Fair Value – 4D ($NASDAQ:FDMT) Molecular Therapeutics is a clinical-stage biopharmaceutical company that specializes in the discovery and development of targeted gene therapies. The company’s stock surged over 25% today after it released a strong earnings report.

Earnings

4D MOLECULAR THERAPEUTICS surged over 25% in stock value today after releasing strong earning results for the second quarter of its 2022 fiscal year. As of June 30, the company had earned a total of 2.8 million dollars in revenue and lost 101.7 million dollars in net income. Compared to the same period last year, this represented a decrease of 84.4% in total revenue.

However, over the last three years 4D MOLECULAR THERAPEUTICS’ total revenue has grown from 13.6 million dollars to 2.8 million dollars. The company’s strong performance this quarter indicates that this trend is likely to continue.

Price History

The stock opened at $8.9 and closed at $8.9, down by 0.6% from prior closing price of 8.9. The company’s strong earnings report was driven by higher revenues and lower expenses.

VI Analysis – FDMT Stock Fair Value

4D Molecular Therapeutics is a clinical-stage biopharmaceutical company that develops gene therapies for the treatment of serious genetic diseases. The company’s fundamentals reflect its long-term potential. The intrinsic value of 4D Molecular Therapeutics’ stock is around $22.2, calculated by VI Line. However, the stock is currently traded at $8.9, representing a significant discount of 60%.

VI Peers

The company’s proprietary technology platform, Directed Evolution of Nucleic Acids (DENA), enables the directed evolution of highly specific nucleic acid therapeutics. 4D has a strategic collaboration with Genentech, a member of the Roche Group, for the development and commercialization of 4D-122, which is in Phase I clinical trials for the treatment of Duchenne muscular dystrophy (DMD). 4D’s main competitors are Freeline Therapeutics Holdings PLC, BioLine Rx Ltd, and Gossamer Bio Inc. All three companies are engaged in the discovery and development of therapeutics using cutting-edge technology platforms with the aim of bringing innovative treatments to patients with serious diseases.

– Freeline Therapeutics Holdings PLC ($NASDAQ:FRLN)

Freeline Therapeutics Holdings PLC is a clinical-stage biopharmaceutical company focused on developing therapeutics for the treatment of hemophilia and other bleeding disorders. The company has a market cap of $49.38 million and a return on equity of -1.18%. Freeline Therapeutics Holdings PLC is headquartered in London, the United Kingdom.

– BioLine Rx Ltd ($NASDAQ:BLRX)

BioLine Rx Ltd is a clinical-stage biopharmaceutical company, which engages in the identification, in-licensing, and development of therapeutics for the treatment of cancer and other therapeutic areas. The company was founded by Philip A. Serlin and Abraham B. Zlotnik on April 21, 2003 and is headquartered in Jerusalem, Israel.

– Gossamer Bio Inc ($NASDAQ:GOSS)

Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on the development of therapeutics in the areas of immunology, oncology, and inflammation. The company’s lead product candidate is GB001, an anti-TNF-alpha antibody being developed for the treatment of inflammatory diseases. GB001 is currently in Phase 1 clinical trials.

Gossamer Bio Inc has a market cap of $990.28M as of 2022 and a Return on Equity of -1952.91%. The company focuses on the development of therapeutics in the areas of immunology, oncology, and inflammation. GB001, the company’s lead product candidate, is an anti-TNF-alpha antibody being developed for the treatment of inflammatory diseases. GB001 is currently in Phase 1 clinical trials.

Summary

Investing in 4D MOLECULAR THERAPEUTICS can be a great way to make money. The company has a strong earnings report and its stock is up over 25%. However, it is important to do your research before investing in any company. You should always consult with a financial advisor to get the most accurate information.